c-Met蛋白在甲状腺癌中的表达及其临床病理意义

目的 检测c-Met 蛋白在甲状腺癌及癌旁甲状腺组织中的表达,并分析c-Met 蛋白表达与甲状腺乳头状癌患者临床病理特征的关系。方法 采用免疫组织化学En Vision二步法检测81 例甲状腺癌组织及52 例癌旁甲状腺组织中c-Met 蛋白的表达。结果 甲状腺癌和癌旁甲状腺组织中c-Met 蛋白阳性率分别为46.9%（38/81）和7.7%（4/52）,两者比较有统计学差异（P＜0.01）。其中甲状腺乳头状癌中c-Met 蛋白阳性率50.8%（31/61）,髓样癌中阳性率60.0%（3/5）,均高于滤泡癌26.7%（4/15）,但均无统计学差异（均P＞0.05）。甲状腺乳头状癌c-Met蛋白表达与患者各项临床病理特征均无相关性（均P＞0.05）。结论 甲状腺癌中c-Met 表达增强,其高表达可能与甲状腺癌发生相关,有望成为抗甲状腺癌治疗的一个潜在靶点。     

稀土β-成核剂对1-丁烯本体聚合和产物聚(1-丁烯)结晶性能的影响

采用Ziegler-Natta催化剂催化1-丁烯本体聚合,稀土β-成核剂经原位聚合的方法加入到体系,并考察成核剂加入量对产物聚(1-丁烯)的分子量和结晶性能的影响.通过凝胶渗透色谱(GPC)、示差扫描量热仪(DSC)、偏光显微镜(POM)和广角X射线衍射仪(WAXD)对聚合物进行表征分析.实验结果表明,随着稀土β-成核剂加入量的增大,催化剂活性有所下降,聚合物等规度略有提高,而聚合的分子量显著提高,分子量分布变窄;聚合时成核剂的加入提高了聚(1-丁烯)的结晶性能,随着成核剂加入量的增多聚合物晶粒变小且尺寸趋向均一化,聚合物结晶度也得到了提高,当成核剂加入量为30 mg时,聚合物结晶度和熔融焓出现突变现象.此外,稀土β-成核剂的加入会改变熔融前聚(1-丁烯)中晶型Ⅰ’和Ⅲ所占比例从而影响聚合物的熔点,成核剂的存在也改变了晶型II向晶型I的转变速率,缩短了晶型转变周期.     

Synthesis,Crystal Structure and I_2 Capture of a Cd(Ⅱ) Coordination Polymer Based on a Linear Bipyridyl Benzene Ligand

A new complex with formula [Cd(3-pbpmb)_2 I_2]_n 1(3-pbpmb = 1,4-bis(pyridine-3-ylmethoxy)benzene), has been solvothermally synthesized and characterized. The crystal belongs to monoclinic system, space group P21/n with a = 8.2905(17), b = 16.078(3), c = 13.213(3) ?, β = 99.44(3)°, Mr = 950.86, V = 1737.3(6) ?~3, Z = 2, Dc = 1.818 g/cm~3, F(000) = 924, m = 2.450 mm~(-1), the final R = 0.0198 and w R = 0.0467 for 3053 observed reflections(I 2σ(I)). The Cd(Ⅱ) ion is coordinated by four N atoms of four 3-pbpmb ligands and two iodine ions to furnish a distorted octahedral coordination geometry. The Cd(Ⅱ) ion and its own symmetry-related ions are bridged by N atoms from two 3-pbpmb ligands to generate a "zigzag" 1-D chain coordination polymer. These 1D chains are further connected into a three-dimensional(3D) framework by C–H×××pinteractions and intermolecular C–H×××I hydrogen bond. Interestingly, 1 displays efficient sorption of molecular iodine gas(up to 111 wt%), but invalid sorption of molecular water gas.